Stock OBD OXFORD BIODYNAMICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Oxford BioDynamics Plc

Equities

OBD

GB00BD5H8572

Biotechnology & Medical Research

Market Closed - London S.E.
Other stock markets
 11:35:27 2024-04-26 am EDT 		5-day change 1st Jan Change
8.1 GBX -1.22% Intraday chart for Oxford BioDynamics Plc -9.90% -71.07%
Apr. 03 Oxford BioDynamics reaches "important milestone" with new laboratory AN
Apr. 03 Oxford BioDynamics Plc Opens Clinical Testing Facility in the UK to Perform EpiSwitch Prostate Screening Blood Test CI

Valuation

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Capitalization 1 198 83.07 94.41 40.96 11.54 74.85
Enterprise Value (EV) 1 179.7 67.57 83.45 43.21 16.68 76.04
P/E ratio -96.1 x -29.7 x -21.9 x -6.13 x -1.71 x -5.04 x
Yield - - - - - -
Capitalization / Revenue 167 x 91.6 x 207 x 120 x 74.9 x 147 x
EV / Revenue 152 x 74.5 x 183 x 127 x 108 x 149 x
EV / EBITDA -79.1 x -20.1 x -18 x -6.3 x -2.09 x -8 x
EV / FCF -77.9 x -32.2 x -30.4 x -6.19 x -4.51 x -16.3 x
FCF Yield -1.28% -3.1% -3.29% -16.2% -22.2% -6.13%
Price to Book 9.88 x 4.73 x 6.96 x 6.14 x 4.46 x 12.4 x
Nbr of stocks (in thousands) 92,506 92,560 92,560 92,560 100,352 202,303
Reference price 2 2.140 0.8975 1.020 0.4425 0.1150 0.3700
Announcement Date 3/14/19 1/23/20 2/23/21 3/1/22 3/21/23 2/22/24
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Net sales 1 1.186 0.907 0.456 0.341 0.154 0.51
EBITDA 1 -2.271 -3.359 -4.63 -6.862 -7.995 -9.51
EBIT 1 -2.602 -3.723 -4.951 -7.512 -8.601 -10.17
Operating Margin -219.39% -410.47% -1,085.75% -2,202.93% -5,585.06% -1,993.73%
Earnings before Tax (EBT) 1 -2.423 -3.386 -4.91 -7.629 -7.567 -11.41
Net income 1 -1.953 -2.8 -4.313 -6.682 -6.71 -10.83
Net margin -164.67% -308.71% -945.83% -1,959.53% -4,357.14% -2,122.75%
EPS 2 -0.0223 -0.0303 -0.0466 -0.0722 -0.0673 -0.0734
Free Cash Flow 1 -2.306 -2.096 -2.742 -6.979 -3.7 -4.658
FCF margin -194.46% -231.08% -601.37% -2,046.7% -2,402.92% -913.36%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/14/19 1/23/20 2/23/21 3/1/22 3/21/23 2/22/24
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - 2.25 5.14 1.19
Net Cash position 1 18.3 15.5 11 - - -
Leverage (Debt/EBITDA) - - - -0.3277 x -0.6425 x -0.125 x
Free Cash Flow 1 -2.31 -2.1 -2.74 -6.98 -3.7 -4.66
ROE (net income / shareholders' equity) -12.3% -14.9% -27.7% -67.3% -145% -251%
ROA (Net income/ Total Assets) -9.67% -11.7% -18.1% -31% -40.2% -46.3%
Assets 1 20.19 23.91 23.8 21.57 16.68 23.4
Book Value Per Share 2 0.2200 0.1900 0.1500 0.0700 0.0300 0.0300
Cash Flow per Share 2 0.2000 0.0600 0.0700 0.0200 0.0100 0.0300
Capex 1 0.44 0.4 0.11 2.69 0.36 0.25
Capex / Sales 37.02% 44.1% 23.46% 789.74% 235.71% 49.02%
Announcement Date 3/14/19 1/23/20 2/23/21 3/1/22 3/21/23 2/22/24
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
OXFORD BIODYNAMICS PLC Stock Oxford BioDynamics Plc
-71.07% 20.41M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. OBD Stock
  4. Financials Oxford BioDynamics Plc